Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am hearing an inkling of a twitching of a spasm as far as news is coming.
Let is see......
That’s why I keep asking
You never get answer to this question!!!
Student Steve - Why are we at 2 months since the long awaited S1 with no updated filing?
Cubt needs more global leadership. Lol
Amen to that!
Steve / Student
How come this whole finance S1 reverse split uplist CRADA trials lawyer SEC whoop de doo isn’t wrapped up yet? Those that invested in you put hard earned dollars on the line. It is overdue.
There is absolutely no basis for anything you are saying. NIH is funding the CRADA and the NYSE/Amex would not even consider uplisting if they wouldn't meet required the shareholder equity. Your speculation is totally off base.
Makes sense. I wasn’t aware of the debt
Meh. All part of trading. But thanks.
The SEC sees something wrong here. Probably the fact that after the offering and funds used to pay off debt, fund the CRADA and salaries for management there will be no cash left. The company is broke again and won’t be able to stay listed without further dilution
I’m sorry to hear
Well if it makes you feel better I am down $100 K on FUTS and close to that on AVVH.
In Trump words.....a total disaster.
That being said I expect both to have their day in the sun. CUBT too if they can ever get this initial financing off of the ground.
I am losing money but not 100k. It’s not horrible like that.
Who govprs or Biden or both?
You understand anything he says? Because I can't.
Just ignore him. Look at his posts. He can't even do simple arithmetic.
You are the one who responded to my messages. If you don't want to interact with me, just shut the f******
Are you bid and supporter? Nothing you are. You are so dumb
If you are so smart and you didn't lose any money in here why you f****** in here?
Stop interacting with me
Accredited investors only buy stocks trading over $5. Losers like you are out 100k cause your not an accredited investor
Make sense yet Mr down 100k penny stock speculator.
Like Biden would say it's a bunch of malarkey
No matter what reverse split is, the market cap is still the same according to the price of the stock so I don't know what you talking about
No what I’m saying is accredited investors are looking at the potential and have doubts because the market cap is sooo low
10000:1 RS coming
So what they say it's so great market billions of dollars market. why they cannot raise just 5 million? It's not that much.
If they have such a great pipeline!
Should say there is plenty of cash floating around!
He’s sharing an opinion. There’s not a ton of truth. There’s no plenty of cash floating around.
So has to get to .13 for a RS 400:1 to get to 5.00
Maybe higher for many accredited investor. Or the RS will need to be 10000:1
Watch
Old news. No guarantee any of it is still true
That goes along with what I am being told.
The financiers I have talked to the past few years say things are becoming much looser lending wise. Which is odd considering interest rates are pretty high.
But I am told that has more to do with mortgages and real estate and not business lending.
Again, as for CUBT I have no idea what that all means other than what I have posted earlier.
If things have dried up what evidence is there that things are beginning to loosen up? I have heard about things loosening up but what evidence is there that companies have actually gotten financed. I don’t follow it that closely but would love to see what companies have actually acquired financing.
No. Because I have no idea as to the inner workings of CUBT management the past 4 years.
What I am saying is the financial money markets completely dried up after covid, and that affected all OTC and SPAC Nasdaq companies.
Hence why you have seen nothing happening movement wise with these entities.
Things are beginning to loosen up though.
So now we're going to blame covid for everything.
Maybe Fauci will be angel investor
There are investors waiting. That I know for sure. The issue is getting the initial 'angel' type investors to get things rolling and the stock price up to a point where more accredited investors will come in. Banks and financiers are more cautions now.
I don't blame CUBT totally. This has been a common thing among OTC companies since covid. There is a reason why the OTC has seen literally no RM's or M&A's since then.
It seems more and more that there is not actually investors who want to invest in the company and the underwriter cannot find anybody to finance
When is it going to happen? It'd be it's been 3 years for crying out loud seems like there is always somebody else to blame for delay. Never companys fault.
The company had 10 days to respond to the comments by SEC and it's been more like 20 and there is still no update to S1
It's worse than promises in politics
Where are things with the Curative S1 and all the next steps? I think we have all waited long enough
Several points:
1. Mid-Atlantic has always had the right to raise funds away from CUBT. If they do so, it would dilute CUBT's interest in the rabies drug, but not replace it.
2. If you read Mid-Atlantic's press release carefully, you will see that they didn't actually raise ANY MONEY. Their funder has the right to sell shares and then buy shares from Mid-Atlantic at a discount WHEN and AFTER Mid-Atlantic goes public; which they say they hope to do in the next 24 months.
3. IMO; this "press release" is all about NOTHING!!!!
4. Remember that CUBT is "focused" on AMD FIRST!! AND the rabies drug is a secondary, back burner drug when CUBT has the funds to move it forward.
Mid-Atlantic BioTherapeutics embarks on the next phase of growth, MABT is poised to make history once again. MABT is excited to announce our pre-IPO round very soon, paving the way for our upcoming NASDAQ listing within the next 24 months.
So are they going at it alone? With or without CUBT??
No idea haha. I would say % wise that you will be fine.
my .10 bid filled today as well as one for .076. 200k total....tell me i didn't make a mistake!!
What I said was certain milestones need to be hit for that money to come in. Still pretty confident that is going to happen.
No insider is going to sell like that. This sell was all within the first minute of trading. For sure a margin call or someone had to sell for whatever reason and because the market was just open there weren't many bids placed yet.
Dumbest move I’ve heard. So tell me which institutions are investing in a capital raise for a stock trading under $5.
You really put 100k into this? Good for you
Followers
|
299
|
Posters
|
|
Posts (Today)
|
5
|
Posts (Total)
|
44362
|
Created
|
03/17/09
|
Type
|
Free
|
Moderators conix Eagle1 Student of the Game trader59 |
OTC: CUBT http://CurativeBiotech.com INVESTOR PRESENTATION https://curativebiotech.com/news-and-media/presentations Curative Biotechnology, a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop an adjuvant for the COVID-19 vaccines which enhance antibody response. Current Drug Pipeline https://curativebiotech.com/pipelineTreatments for six (6) Ocular conditions, one (1) Oncology, one (1) Infectious disease and one (1) vaccine adjunct candidate* Metformin eyedrops for treatment of Acute Macular Degeneration (AMD) AMD is a visually threatening condition, most often found in patients over age 60. Early and Intermediate AMD are characterized by enlarged drusen behind the eye’s retina. Close to 10% of the world’s population is over 60, increasing the prevalence of age-related macular degeneration. Dry AMD accounts for 80-90% of AMD cases, while wet AMD is 10-20% of cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late stage dry AMD). Wet AMD is caused by blood vessels that leak in the retina. These abnormal blood vessels may leak fluids or blood into the back of the eye. Curative Biotech will reformulate metformin to treat intermediate dry AMD and Geographic Atrophy for the first indications. Development to be led by the lead inventor on the NEI Patents, Dr. Kapil Bharti. Curative is in negotiations with NEI to conduct the first clinical trial. This product may be eligible for 505(b)(2) treatment as a reformulation of an already approved drug. The global age-related macular degeneration (AMD) market is expected to attain a value of $8.9 billion by 2022 Stargardt DiseaseStargardt disease is a type of inherited age-related macular degeneration that causes vision loss in children or young adults.The retina contains light-sensing cells called photoreceptors, which include rods and cones. Rods are in the outer retina and help people when lighting is dim and dark. Cones are in the macula and help people see intricate visual detail and color. Both cones and rods negatively affected in Stargardt disease, cones are more strongly impacted in people who have Stargardt disease. The Global Stargardt Disease Therapeutics Market is estimated to be valued at US$ 213.5 million in 2023 and is expected to exhibit a CAGR of 31.7% during the forecast period (2023 - 2028). Retinitis PigmentosaRetinitis pigmentosa (RP) is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. People with RP experience a gradual decline in their vision, because photoreceptors degenerate. Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells. Retinitis Pigmentosa (RP), an acquired retinal condition that causes retinal depletion, is an uncommon illness. Its underlying manifestations are decreased night vision along with loss of fringe vision. It slowly causes visual impairment. There is no conclusive remedy for retinitis pigmentosa. Hence medical institutions and various research and development centers are researching to develop a full proof cure for this disease which is boosting the growth of global retinitis pigmentosa market. ChoroideremiaChoroideremia is a hereditary degeneration of the retina in males that causes a gradual loss of vision. It starts in early childhood with night-blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. The lack of a functional protein in the retina causes cell death that is followed by the gradual deterioration of the retinal pigment epithelium, photoreceptors, and the choroid. Choroideremia results in progressive loss of vision and is more prominent in males. The first symptom of choroideremia is usually night blindness that occurs at an early stage. Global Choroideremia Treatment market is expected to account for $4.3 Billion by 2028 Late Onset Retinal DegenerationLate-onset retinal degeneration occurs in adulthood and is an inherited retinal dystrophy. It leads to central vision loss. https://www.sciencedaily.com/releases/2021/12/211209133927.htm Diabetic RetinopathyDiabetic retinopathy is the leading cause of blindness in adults. It is a complication of diabetes that causes damage to the blood vessels of the retina. At first, diabetic retinopathy may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The global diabetic retinopathy market reached a value of US$ 7.64 Billion in 2020. and is expected to register a CAGR of 7.6% over the forecast period. Market growth can be primarily attributed to increased funding by regulatory bodies for researching ocular disorders. REFERENCE LINK: https://curativebiotech.com/pipeline |
From 1990 to 2017, worked at National Cancer Insitute of the NIH. Since 2017 Director of Center for Antibody Therapeutics at University of Pittsburgh. Dr. Dimitrov’s major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies in different formats including engineered antibody domains, chimeric antigen receptors, bispecific antibodies and antibody drug conjugates. He has authored or coauthored more than 370 articles, several books, and is the inventor or coinventor of more than 100 inventions, patent applications or patents. Dr. Dimitrov is the lead inventor on the Antibody Drug Conjugate patent exclusively licensed to Curative Biotech from the National Cancer Institute to treat glioblastoma.
Currently President of Sohn Health Strategies and Adjunct Professor at the University of California, San Francisco.
Dr. Sohn has deep biopharmaceutical industry knowledge with over thirty (30) years of U.S. and global experience with expertise in the development and introduction of new medicines for patients and diseases with significant unmet needs. Her skill sets include strategic product development, business development and the introduction of new vaccines, pharmaceutical products and consumer healthcare brands.
Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee. Subsequently, she led the US commercialization of the company’s largest CNS product. Dr. Sohn later became senior vice president, Worldwide Business Development and a member of the global executive committee at GlaxoSmithKline Consumer Healthcare where she led U.S. and global transactions, including the $1.3 billion acquisition and integration of Block Drug and the $566 million acquisition of CNS, Inc.
Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits.
Paul Michaels, Chairman and President of Curative Biotechnology, said, "We are pleased to announce the successful completion of these important studies, outlined in our Pre IND meeting with the FDA. We are now able to move on to preparing the Company's first IND application to move our Metformin reformulation into a clinical trial to treat Intermediate Dry Age-Related Macular Degeneration (AMD) and Geographical Atrophy (GA) resulting from AMD."
Michaels continued, "Both Dry AMD and GA are currently unmet medical needs with no FDA approved efficacious treatment options. As previously announced, we will be conducting the first in human study under a CRADA (Cooperative Research and Development Agreement) with the National Eye Institute of the National Institutes of Health, in Bethesda Maryland."
About Macular Degeneration (AMD)
Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).
About Curative Biotechnology, Inc. http://curativebiotech.com
Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The Company's pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a novel immune therapy to treat rabies and an adjuvant for vaccines. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation is targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
Contact:
Steve Chizzikhttps://www.wsj.com/articles/curative-biotechnology-announces-completion-of-ind-enabling-reformulated-metformin-hcl-eye-drop-study-01672923305
Connectyx (now Curative Botechnology) Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease
Boca Raton, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD).
The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide.
The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.
Research has shown that Metformin, an FDA-approved drug that has been widely used for the treatment of diabetes in the United States since 1995, can activate AMP-activated protein kinase, can reduce vascular endothelial growth factor (VEGF) secretion, and can correct baseline calcium levels in patient RPE cells. The new treatment indications will require reformulating the drug into an eye drop, injectable or other topical delivery method to be able to deliver sufficient drug to the RPE layer to have a therapeutic effect. This reformulated drug should be eligible for a 505(b)(2) accelerated development path. While the field of use covers treating any degenerative eye disease, the Company is targeting Stargardt, a currently untreatable orphan disease that causes vision loss in children, as the first indication for this therapeutic product.
Paul Michaels, Chairman and President of Connectyx, said, “We are pleased to expand our product portfolio with the addition of reformulated and repurposed Metformin, which is the fifth most prescribed drug in the United States. This very promising product adds a second in licensed product from the NIH to our development portfolio. As stated above, we believe our Metformin reformulation may show efficacy in treating a wide range of RD diseases that cause vision loss. We are focused on developing disease modifying therapeutics to meet the unmet needs of patients. The Company anticipates being prepared for human testing of this reformulation by third quarter of 2022.”
About Age-Related Macular Degeneration, Stargardt Disease, Retinitis Pigmentosa and Choroideremia
AMD is the leading cause of vision loss in people ages 60+. It destroys a patient’s sharp, central vision. Stargardt disease is a type of AMD that causes vision loss in children or young adults. Retinitis pigmentosa is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. Choroideremia is a hereditary retinal degeneration that causes a gradual loss of vision. It starts in early childhood with night blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. Diabetic retinopathy is the leading cause of blindness in adults. Diabetes harms blood vessels inside the eye by weakening them so they leak fluid into the retina, which can damage areas of the retina, causing blurry, distorted vision.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |